FDA Expands J&J's Tremfya Label To Slow Joint Damage In Psoriatic Arthritis

The U.S. Food and Drug Administration on May 29, 2026 broadened the approved use of Johnson & Johnson's (NYSE: JNJ) blockbuster drug Tremfya, now clearing it to inhibit the progression of structural joint damage in adults with active psoriatic arthritis. The regulatory decision adds to the IL-23 inhibitor's existing indications for plaque psoriasis and psoriatic arthritis symptom management. J&J’s Janssen Pharmaceutical unit said the expanded label is supported by data from long-term extension studies showing Tremfya significantly reduced radiographic joint erosion compared to standard therapy. Shares of the Dow component were little changed in early trading. Tremfya generated $3.7 billion in global sales in 2025, and the new joint-protection claim could bolster its competitive position in the immunology market against rivals such as AbbVie's Skyrizi. Psoriatic arthritis affects an estimated 2 million adults in the U.S., with up to half developing irreversible joint damage within two years of diagnosis.